Study Investigating the Role of Oxaliplatin Duration in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Colon Cancer Therapy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01092481 |
Recruitment Status : Unknown
Verified May 2019 by Young Suk Park, Samsung Medical Center.
Recruitment status was: Active, not recruiting
First Posted : March 25, 2010
Last Update Posted : May 21, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Colon Cancer | Drug: oxaliplatin | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 1580 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomized Phase III Study Investigating the Role of Oxaliplatin Duration (3 Months Versus 6 Months) in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Therapy for Patients With Stage II/III Colon Cancer |
Actual Study Start Date : | January 26, 2010 |
Estimated Primary Completion Date : | December 2019 |
Estimated Study Completion Date : | December 2019 |
Arm | Intervention/treatment |
---|---|
Active Comparator: FOLFOX_12 or CAPOX_8
6 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX
|
Drug: oxaliplatin
to confirm that first 3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX treatment is not inferior to 6 months of oxaliplatin in modified FOLFOX-6 or CAPOX treatment in terms of disease free survival in patients with stage II/III colon cancer.
Other Name: oxaliplatin (modified FOLFOX-6 OR CAPOX) |
Experimental: FOLFOX_6 or CAPOX_4
3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX
|
Drug: oxaliplatin
to confirm that first 3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX treatment is not inferior to 6 months of oxaliplatin in modified FOLFOX-6 or CAPOX treatment in terms of disease free survival in patients with stage II/III colon cancer.
Other Name: oxaliplatin (modified FOLFOX-6 OR CAPOX) |
- disease-free survival [ Time Frame: 3 years ]
- overall survival [ Time Frame: 3 years ]
- quality of life [ Time Frame: 3 years ]
- safety profiles [ Time Frame: 3 years ]Safety will be assessed on the basis of an analysis of adverse events, standard clinical chemistry and hematology findings. Clinical and laboratory toxicities/symptoms will be graded according to the CTCAE 3.0. Adverse events which are not reported in CTCAE 3.0 will be graded as mild, moderate, severe or life threatening.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Curatively resected, histologically confirmed colon adenocarcinoma
- AJCC/UICC high-risk stage II, stage III colon cancer
- Age over 18 years old
- Performance status (ECOG scale): 0-1
- Adequate major organ functions
- Patients should sign a written informed consent before study entry
Exclusion Criteria:
- Colon cancer other than adenocarcinoma
- Rectal cancer
- R1 or R2 resections
- Other malignancies within the last 5 years
- Symptomatic peripheral sensory neuropathy
- Presence of other serious disease
- Lactating or pregnant women
- Fertile women
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01092481
Principal Investigator: | Young Suk Park, M.D.,Ph.D. | Samsung Medical Center, Seoul, Korea |
Responsible Party: | Young Suk Park, Professor, Samsung Medical Center |
ClinicalTrials.gov Identifier: | NCT01092481 |
Other Study ID Numbers: |
2009-11-008 2009-11-008 ( Other Identifier: Samsung Medical Center ) |
First Posted: | March 25, 2010 Key Record Dates |
Last Update Posted: | May 21, 2019 |
Last Verified: | May 2019 |
Adjuvant FOLFOX or CAPOX Therapy Stage II/III Colon Cancer Adjuvant Therapy |
Colonic Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms |
Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Oxaliplatin Antineoplastic Agents |